17th November 2017 – Aravax today signed a collaborative agreement with Stanford University in California. The Stanford research group, led by Professor Kari Nadeau, will collaborate with Aravax to further explore immunological responses to Aravax's revolutionary peanut allergy therapy, PVX108. Professor Kari Nadeau is one of the foremost experts in adult and pediatric allergy and asthma and is the Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. As part of the collaborative agreement, Professor Kari Nadeau's group will receive clinical samples from Aravax's ongoing clinical trial, AVX001.
PVX108 utilises peptides that represent carefully selected fragments of peanut proteins to switch off allergic reactions to peanuts. Unlike other peanut allergy immunotherapies under development, the peptides do not contain the parts of the peanut proteins that cause life-threatening anaphylactic reactions. This collaboration now involves Aravax, Stanford University, and the Benaroya Research Institute and will enable further testing of PVX108 used in our clinical trial, which is expected to be completed the second half of 2018.
Pascal Hickey, CEO of Aravax said "Aravax is proud to expand our collaborative efforts and announce the addition of Stanford University to the ongoing research we are conducting with the Benaroya Research Institute. We look forward to the completion of our phase 1 clinical trials."